{"id":43182,"date":"2026-07-23T15:06:00","date_gmt":"2026-07-23T13:06:00","guid":{"rendered":"http:\/\/stocks-future.com\/?guid=89b0a74cebb28024f336dd84a321e354"},"modified":"2026-07-24T21:35:00","modified_gmt":"2026-07-24T19:35:00","slug":"evoendo-surpasses-3000-sedation-free-transnasal-endoscopy-procedures-nationwide-2","status":"publish","type":"post","link":"https:\/\/stocks-future.com\/?p=43182","title":{"rendered":"EvoEndo\u00ae Surpasses 3,000 Sedation-Free Transnasal Endoscopy Procedures Nationwide"},"content":{"rendered":"

CHICAGO--(BUSINESS WIRE)--#FEEES<\/a>--EvoEndo\u00ae<\/sup>, Inc.<\/a> (EvoEndo) today announced that practitioners have now completed more than 3,000 sedation-free transnasal endoscopy (TNE) procedures using the EvoEndo Endoscopy System, as implementation expands to more than 70 locations nationwide.<\/p><\/a><\/a>

\n\u201cReaching 3,000 cases is an important milestone, but what matters most is what it represents for patients, families, and physicians,\u201d said Jonathan Hartmann, CEO of EvoEndo. \u201cEvery case reflects greater access to sedation-free endoscopy and the trust our partners place in EvoEndo.\u201d<\/p>

\nEvoEndo's footprint now extends from Boston to San Francisco, including sites in Philadelphia, Cleveland, Milwaukee, Birmingham, and Orlando. At Phoenix Children's Hospital, an early adopter, practitioners have completed more than 300 procedures.<\/p>

\nMore than 100 practitioners have adopted the EvoEndo Endoscopy System. \u201cWe have been thrilled to offer our patients a less invasive option for managing and monitoring their eosinophilic esophagitis,\u201d said Dr. Eitan Rubinstein, Assistant Professor in Pediatrics at Harvard Medical School and Attending Physician in the Department of Gastroenterology and Nutrition at Boston Children\u2019s Hospital.<\/p>

\nDr. Aravind Thavamani, Pediatric Gastroenterologist at University Hospitals Rainbow Babies & Children\u2019s Hospital, said, \u201cTNE has changed the way I approach endoscopy in my pediatric patients \u2014 no sedation, no recovery room, and a child who walks out the door minutes after the procedure. EvoEndo\u2019s platform gives me the tools to make that a reality with enhanced diagnostic capability.\u201d<\/p>

\nEvoEndo continues to expand access to sedation-free endoscopy across hospitals, clinics, and satellite locations nationwide. Patients and families can learn more at evoendopatient.com<\/a>, and physicians interested in the EvoEndo Endoscopy System can request information at evoendo.com<\/a>.<\/p>

\nAbout EvoEndo<\/a><\/p>

\nEvoEndo, Inc. is a medical device company developing systems that enable sedation-free endoscopic procedures with sterile single-use, flexible endoscopes for both adult and pediatric patients.<\/p>

\nThe EvoEndo\u00ae Model LE Gastroscope<\/a> is intended for the visualization of the upper digestive tract in adults and pediatric patients, specifically for the observation, diagnosis, and endoscopic treatment of the esophagus, stomach, and duodenal bulb. The gastroscope is a sterile single-use device and can be inserted orally or transnasally. The 110 cm gastroscope is intended to be used in adult and pediatric populations. The 85 cm gastroscope is intended to be used in the pediatric population. The EvoEndo Controller is intended for use with an EvoEndo Endoscope for endoscopic diagnosis, treatment, and video observation.<\/p>

\n\u00a9 2026 EvoEndo, Inc. US: Rx only. For use by trained physicians only.<\/p> Contacts<\/b>

\nMedia Contact\n<\/b>EvoEndo, Inc.\nPaula Rocha\nprocha@evoendo.com<\/a>303.276.5753<\/p>","protected":false},"excerpt":{"rendered":"

CHICAGO–(BUSINESS WIRE)–#FEEES–EvoEndo\u00ae, Inc. (EvoEndo) today announced that practitioners have now completed more than 3,000 sedation-free transnasal endoscopy (TNE) procedures using the EvoEndo Endoscopy System, as implementation expands to more t…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-43182","post","type-post","status-publish","format-standard","hentry"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/43182","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=43182"}],"version-history":[{"count":3,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/43182\/revisions"}],"predecessor-version":[{"id":44863,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/43182\/revisions\/44863"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=43182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=43182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=43182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}